Spinraza

Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s partner Biogen Inc (NASDAQ: BIIB) reported fourth-quarter results Wednesday before the market open, revealing that sales of the spinal muscular atrophy treatment Spinraza came in at $470 million, missing the consensus estimate. Spinraza was...

PTC Therapeutics, Inc. (NASDAQ: PTCT) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies. The Rating William Blair analyst Raju Prasad accordingly upgraded PTC to Outperform. The Thesis Risdiplam’s efficacy data compares...

Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...

Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside.  The Rating UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410. The Thesis Biogen’s...

Analysts at Citi no longer hold a bullish view on Biogen Inc (NASDAQ: BIIB). The firm's Robyn Karnauskas downgraded Biogen's stock rating from Buy to Neutral with a new $360 price target. A prior bullish stance on Biogen's stock has been in place since early February and was due to strong...

Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...

While risks to the stock still remain, UBS has upgraded Biogen Inc (NASDAQ: BIIB) from Sell to Neutral and has raised its price target for the stock from $262 to $270. At this point, the risks are fully priced into the stock, analyst Carter Gould wrote on Monday. “In our view, the competitive...

Morgan Stanley’s Matthew Harrison expects Biogen Inc (NASDAQ: BIIB) to trade in line with the group, after appreciating following the Bioverativ Inc (NASDAQ: BIVV) spinoff and expectations related to Spinraza. The analyst downgraded Biogen from Overweight to Equal-weight, while lowering the...

Leerink's Global Healthcare Conference kicked off Wednesday and will continue through Thursday. Here is a summary of what Leerink's analysts are saying about some of the notable companies who presented at on Wednesday. Universal Health Services Universal Health Services, Inc. (NYSE: UHS)'s chief...

Baird Equity Research expects to see a “less-than-optimal Tecfidera performance” when Biogen Inc (NASDAQ: BIIB) issues its fourth-quarter earnings January 26. The psoriasis treatment is predicted to fall short of sales revenue consensus by $45 million after scripts fell more than 6...

The U.S. Food and Drug Administration approved in late December Ionis Pharmaceuticals Inc's (NASDAQ: IONS) therapy for the treatment of spinal muscular atrophy called Spinraza. In a research report on Friday, Jefferies' Eun Yang suggested that Spinraza is Ionis' only exciting...

Following the FDA's December approval of Spinraza, Biogen Inc (NASDAQ: BIIB)'s commercial form of nusinersen for the treatment of spinal muscular atrophy, Cantor Fitzgerald analysts warned that the drug may provoke a now-latent debate on drug prices. "We wonder whether 2017 could start with a...

BMO Capital raised its price target on Ionis Pharmaceuticals Inc (NASDAQ: IONS) shares to $68 from $61 after the brokerage increased its Spinraza estimates to reflect a faster ramp based on the broad approval and a higher price point announced by partner Biogen Inc (NASDAQ: BIIB). Spinraza To...

Biogen Inc (NASDAQ: BIIB) shares were seen up 2.9 percent and Ionis Pharmaceuticals Inc (NASDAQ: IONS) up 4.42 percent on Tuesday following news that the FDA has approved Spinraza for treatment of spinal muscular atrophy. At the same time, shares of rival drug maker AveXis Inc (NASDAQ: AVXS) were...